Gefitinib tablets

Ioversol is an organoiodine compound that used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups.

Strength: 320mg I/ml (50ml; 100ml)

Dossiers are in preparation for US-FDA approval.

Azilsartan is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. Strength: 20mg, 40mg
Standard: In-house

It is a kind of analgesics.

Strength: 4mg/2ml, 1mg/1ml


Standard: In-house

Dutasteride is a triple 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone. It is used to treat benign prostatic hyperplasia. It increases the risk of erectile dysfunction and decreased sexual desire.

Strength: 0.5mg


Standard: In-house

Etoposide or VP-16 is a cytotoxic anticancer drug which belongs to thetopoisomerase inhibitor drug class. It is used as a form of chemotherapy for cancers such as Kaposi’s sarcoma, Ewing's sarcoma, lung cancer, testicular cancer, lymphoma, nonlymphocytic leukemia, and glioblastoma multiforme. It is often g...

It is indicated for gout.

Strength: 20mg, 40mg, 80mg


Standard: In-house

Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent with a quaternary ammonium structure. A muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics. 
Strength:&nb...

It is indicated for breast cancer.

Strength: 6mg/0.6ml


Standard: In-house

Ondansetron is a competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. Strength: 4mg, 8mg
Standard: In-house

It is a kind of analgesics.

Strength: 40mg


Standard: In-house

It is used to treat high parathyroid hormone levels in certain patients.
Strength: 5mcg/1ml

Standard: In-house.

Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement).It is still in R&D stage, and estimated approved in 2020.

Hengrui Medicine is dedicated to research, developing, and promoting innovative medicine with high quality.